

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



丽珠医药  
LIVZON

麗珠醫藥集團股份有限公司

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **CANCELLATION OF SHARE OPTIONS UNDER THE 2018 SHARE OPTIONS INCENTIVE SCHEME**

Reference is made to the announcements of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 17 July 2018, 18 July 2018, 29 July 2018, 17 August 2018, 31 August 2018, 5 September 2018, 11 September 2018, 8 October 2018, 28 August 2019, 18 September 2019, 16 October 2019, 20 November 2019, 23 October 2020, 2 November 2020, 9 November 2020 and 10 November 2021, and the circular of the Company dated 18 August 2018 (the “**Circular**”) in relation to, among others, the proposed adoption of the 2018 Share Options Incentive Scheme (Revised Draft) (the “**Incentive Scheme**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

In view of the third exercise period under the First Grant having expired on 27 September 2022 and the second exercise period under the Reserved Grant having expired on 27 October 2022, as at the expiration date, there were a total of 4,858,821 Share Options held by 746 Incentive Participants during the exercise period under the First Grant which were not yet exercised and there were a total of 45,278 Share Options held by 14 Incentive Participants during the exercise period under the Reserved Grant which were not yet exercised. Furthermore, there were a total of 913 Share Options no longer satisfying the conditions for incentive due to the appraisal results of individual performance of 2 Incentive Participants under the First Grant.

According to the Incentive Scheme and the mandate granted by the EGM, A Shareholders' Class Meeting and H Shareholders' Class Meeting to the Board to deal with matters regarding the Incentive Scheme, the Company intends to cancel the above-mentioned 4,905,012 Share Options which have expired but were not yet exercised and no longer satisfying the conditions for incentive.

By order of the Board

麗珠醫藥集團股份有限公司

**Livzon Pharmaceutical Group Inc. \***

**Yang Liang**

*Company Secretary*

Zhuhai, China

17 February 2023

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.*

*\* For identification purpose only*